Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting

Haematologica

Volumn 99, Issue 12, 2014, Pages e260-e263

  Venner, Christopher P ^a,b   Gillmore, Julian D ^a   Sachchithanantham, Sajitha ^a   Mahmood, Shameem ^a   Lane, Thirusha ^a   Foard, Darren ^a   Rousse, Murielle ^a,c   Rannigan, Lisa ^a   Gibbs, Simon D J ^a,d   Pinney, Jennifer H ^a   Whelan, Carol J ^a   Lachmann, Helen J ^a   Hawkins, Philip N ^a   Wechalekar, Ashutosh D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CHU PURPAN   (France)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Amyloidosis; Patient selection; Stem cell transplantation

Indexed keywords

ALKALINE PHOSPHATASE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; TROPONIN T; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; END STAGE RENAL DISEASE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY FAILURE; LETTER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT SELECTION; PLASMA CELL DYSCRASIA; PROGRESSION FREE SURVIVAL; PROTEIN URINE LEVEL; TREATMENT OUTCOME; AUTOTRANSPLANTATION; CANCER STAGING; COHORT ANALYSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84919362791     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.108191     Document Type: Letter

References (26)

1. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118(16):4346-52.
2. Goodman HJB, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol. 2006;134(4):417-25.
3. Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Hayman SR, Buadi F, et al. Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006. Amyloid. 2001;18(Suppl 1):137-8.
4. Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M, et al. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney Int. 2003;63(5):1868-73.
5. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-9.
6. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-7.
7. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. J Clin Oncol. 2012;30(9):989-95.
8. Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA, Saenger AK, et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart. 2014;100(5):383-8.
9. Girnius S, Seldin DC, Cibeira MT, Sanchorawala V. New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation. J Clin Oncol. 2013;31(21):2749-50.
10. Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119(5):1117-22.
11. Jimenez-Zepeda VH, Franke N, Reece DE, Trudel S, Chen C, Delgado DH, et al. Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution. Br J Haematol. 2013;164(5):722-8.
12. Cordes S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer. 2012;118 (24):6105-9.
13. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083-93.
14. Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2013:99(4):743-50.
15. Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457-64.
16. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119(21):4860-7.
17. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012;119(23):5384-90.
18. Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica. 2013;98(3):433-6.
19. Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010;116(23):4777-82.
20. Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013;98(5):789-92.
21. Mahmood S, Venner CP, Sachchithanantham S, Lane T, Rannigan L, Foard D, et al. Lenalidomide and dexamethasone for Systemic AL Amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol. 2014;166(6):842-8.
22. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4.
23. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Buadi FK, Dingli D, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2010;46(7):970-5.
24. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557-61.
25. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study. Br J Haematol. 2006;134(4):385-90.
26. Leung N, Dispenzieri A, Lacy MQ, Kumar SK, Hayman SR, Fervenza FC, et al. Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain-Associated Amyloidosis after Autologous Stem Cell Transplantation. Clin J Am Soc Nephrol. 2007;2(3):440-4.